Sirolimus-eluting Stent CALYPSO vs Everolimus-eluting Stent XIENCE

Launched by MESHALKIN RESEARCH INSTITUTE OF PATHOLOGY OF CIRCULATION · Feb 11, 2016

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients considered for coronary angioplasty with stenting due to Ischemic heart disease (Stable angina, Unstable angina, non-ST Myocardial Infarction).
• • Target vessel lesion in coronary artery with diameter measurements \>2.5 mm \& \< 4.5 mm.
• • Signed, documented informed consent prior to admission to the study
• Exclusion Criteria:
• • Age \<18 years or \>75 years
• • Renal insufficiency (GFR/MDRD \<30 ml/min)
• • Subject has a platelet count \< 100,000 cells/mm3 or \> 700,000 cells/mm3.
• • Known non-adherence to DAPT
• • LVEF \<30%
• • Known oncology
• • Severe cardiac valvular pathology, requiring operative treatment within 1 year
• • Anemia (HB\<100 g/l)
• • Continuing bleeding
• • Acute coronary syndrome (ST-elevation Myocardial infarction)
• • Anamnesis of previous coronary angioplasty/stenting or CABG
• • NYHA class (dyspnoea) IV or hospitalization during last year due to Chronic cardiac failure as a primary diagnosis.
• • Pregnancy
• • Coronary pathology requiring CABG or staged scheduled coronary angioplasty/stenting except cases of unscheduled staged coronary angioplasty/stenting within 4 weeks after primary procedure.